SYMTUZA Drug Patent Profile

Which patents cover Symtuza, and what generic alternatives are available?

Symtuza is a drug marketed by Janssen Prods and is included in one NDA. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has four hundred and twenty-three patent family members in forty-six countries.

The generic ingredient in SYMTUZA is cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate profile page.

DrugPatentWatch^® Generic Entry Outlook for Symtuza

Symtuza was eligible for patent challenges on November 5, 2019.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 6, 2032. This may change due to patent challenges or generic licensing.

There have been twenty-seven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for SYMTUZA

International Patents:	423
US Patents:	6
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SYMTUZA

Paragraph IV (Patent) Challenges for SYMTUZA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SYMTUZA	Tablets	cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate	800 mg/150 mg/ 200 mg/10 mg	210455	1	2021-08-16

US Patents and Regulatory Information for SYMTUZA

SYMTUZA is protected by thirteen US patents.

This potential generic entry date is based on patent 10,039,718.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Prods	SYMTUZA	cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210455-001	Jul 17, 2018		RX	Yes	Yes	8,754,065		Y	Y
Janssen Prods	SYMTUZA	cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210455-001	Jul 17, 2018		RX	Yes	Yes	10,786,518
Janssen Prods	SYMTUZA	cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210455-001	Jul 17, 2018		RX	Yes	Yes	10,039,718		Y
Janssen Prods	SYMTUZA	cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210455-001	Jul 17, 2018		RX	Yes	Yes	9,296,769		Y	Y
Janssen Prods	SYMTUZA	cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210455-001	Jul 17, 2018		RX	Yes	Yes	8,148,374		Y	Y

International Patents for SYMTUZA

When does loss-of-exclusivity occur for SYMTUZA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

African Regional IP Organization (ARIPO)

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Hong Kong

Hungary

Israel

Japan

Mexico

New Zealand

Peru

Poland

Portugal

San Marino

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SYMTUZA around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	513200
Hungary	E025822
Peru	20141328	TENOFOVIR ALAFENAMIDA HEMIFUMARATO
Norway	923014
Canada	3070713	COMPOSITIONS COMPRENANT DU DARUNAVIR, DU COBICISTAT, DE L'EMTRICITABINE ET DU TENOFOVIR ALAFENAMIDE POUR UNE UTILISATION DANS LE TRAITEMENT DU VIH (COMPOSITIONS COMPRISING DARUNAVIR, COBICISTAT, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FOR USE IN THE TREATMENT OF HIV)

Supplementary Protection Certificates for SYMTUZA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2049506	C20150046 00250	Estonia		PRODUCT NAME: KOBITSISTAAT;REG NO/DATE: EU/1/13/830/001-002 27.05.2013
0513200	300148	Netherlands		300148, 20110131, EXPIRES: 20160130
1301519	C01301519/01	Switzerland		PRODUCT NAME: TENOFOVIRALAFENAMID; REGISTRATION NO/DATE: SWISSMEDIC AUTHORISATION 65793 01.09.2016
2049506	C02049506/01	Switzerland		PRODUCT NAME: COBICISTAT; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 62673 18.10.2013
2049506	15C0078	France		PRODUCT NAME: COBICISTAT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE COBICISTAT; REGISTRATION NO/DATE: EU/1/13/830/001-002 20130527

SYMTUZA (Dolutegravir/Lamivudine/Tenofovir Disoproxil Fumarate) Investment Analysis

Last updated: February 19, 2026

Symtuza, a fixed-dose combination (FDC) tablet containing dolutegravir, lamivudine, and tenofovir disoproxil fumarate (TDF), presents a notable investment prospect within the antiretroviral therapy market. Its development and market penetration are underpinned by established efficacy, a favorable regimen profile, and a broad intellectual property (IP) landscape. This analysis examines the fundamental drivers and investment considerations for Symtuza.

What is the Market Opportunity for Symtuza?

The global market for HIV/AIDS therapeutics is substantial and projected for continued growth, driven by increasing diagnosis rates, expanded access to treatment programs, and the need for optimized therapeutic regimens. Symtuza addresses key market demands by offering a single-tablet regimen (STR) that simplifies treatment, potentially improving adherence and reducing the burden of managing multiple pills.

The World Health Organization (WHO) recommends dolutegravir-based regimens as a preferred first-line and second-line treatment for HIV-1 infection in adults and adolescents. This recommendation significantly bolsters the market potential for FDCs containing dolutegravir, including Symtuza. The global burden of HIV remains high, with approximately 38.4 million people living with HIV as of 2021, and 1.5 million new HIV infections in the same year [1]. Treatment access remains a critical factor, and STRs are instrumental in facilitating this access, particularly in resource-limited settings.

The market opportunity for Symtuza is also influenced by:

• Anticipated growth in emerging markets: Sub-Saharan Africa, Asia, and Latin America represent significant markets with high HIV prevalence and increasing investment in healthcare infrastructure and treatment programs.
• Demand for simplified regimens: The transition from multi-pill regimens to STRs is a well-established trend in HIV management, driven by patient preference and healthcare provider recommendations for improved adherence and reduced pill burden.
• Competition from other STRs: While Symtuza is a strong contender, the market includes other dolutegravir-containing STRs and integrase strand transfer inhibitor (INSTI)-based regimens, requiring ongoing differentiation.

What are the Key Components and Their Clinical Significance?

Symtuza is a complete antiretroviral regimen comprising three active pharmaceutical ingredients (APIs) with distinct mechanisms of action, targeting different stages of the HIV replication cycle.

• Dolutegravir (DTG): This is an integrase strand transfer inhibitor (INSTI). It works by blocking the integrase enzyme, which HIV uses to integrate its genetic material into the host cell's DNA. Dolutegravir has demonstrated high efficacy, a favorable resistance profile, and generally good tolerability compared to older INSTIs [2]. Its potency allows for lower doses and contributes to its incorporation into preferred treatment guidelines.
• Lamivudine (3TC): This is a nucleoside reverse transcriptase inhibitor (NRTI). It acts by inhibiting the reverse transcriptase enzyme, an essential enzyme for HIV replication. Lamivudine is a well-established NRTI with a long history of use in combination therapies.
• Tenofovir Disoproxil Fumarate (TDF): This is another NRTI. It is a prodrug of tenofovir, which is phosphorylated intracellularly to its active diphosphate form. TDF also inhibits reverse transcriptase. While TDF has been a backbone of HIV therapy for years, its use is associated with potential renal and bone mineral density adverse effects, leading to the development of tenofovir alafenamide (TAF) as a lower-dose, potentially safer alternative in some formulations. Symtuza utilizes TDF.

The combination of these three APIs provides a potent, multi-pronged attack on the virus, reducing the likelihood of viral resistance developing. The FDC format ensures that all three components are taken in a single pill, simplifying adherence and potentially improving patient outcomes.

What is the Intellectual Property (IP) Landscape for Symtuza?

The IP surrounding Symtuza is critical for its commercial viability and market exclusivity. The patent landscape involves patents covering the active pharmaceutical ingredients, the fixed-dose combination itself, manufacturing processes, and specific formulations.

Key aspects of the IP landscape include:

• Composition of Matter Patents: Patents covering dolutegravir, lamivudine, and tenofovir disoproxil fumarate themselves, which have varying expiry dates based on their initial discovery and patent filings.
• Formulation Patents: Patents protecting the specific FDC tablet formulation of Symtuza, which may include aspects like particle size, excipients, and tablet structure designed for stability, dissolution, and bioavailability.
• Method of Use Patents: Patents covering the use of the FDC for treating HIV infection.
• Manufacturing Process Patents: Patents related to the synthesis and production of the individual APIs and the final FDC product.

The development of generic versions of Symtuza is contingent upon the expiry of key patents. Companies holding patents for the individual components and the combination can pursue legal avenues to defend their IP against potential infringements by generic manufacturers. The complexity of patent protection often involves multiple patents with overlapping durations, requiring careful analysis to determine periods of market exclusivity.

For Symtuza, the patent expiry dates are crucial for projecting future revenue streams and identifying windows of opportunity for generic competition. Companies will also need to consider patent litigation risks and potential challenges to patent validity.

What is the Competitive Landscape for Symtuza?

Symtuza operates in a competitive market characterized by rapid innovation and the presence of multiple therapeutic options. Its primary competitors can be categorized as follows:

• Other Dolutegravir-Containing STRs: Several pharmaceutical companies offer STRs that include dolutegravir in combination with other antiretroviral agents. Examples include:

  • Triumeq (Abacavir/Dolutegravir/Lamivudine): While also an INSTI-based STR, it uses abacavir and lamivudine instead of TDF. It has a different genetic screening requirement (HLA-B*5701 testing) due to the risk of hypersensitivity reactions with abacavir.
  • Juluca (Dolutegravir/Rilpivirine): A two-drug regimen for virologically suppressed adults, offering an alternative for maintenance therapy.
  • Dovato (Dolutegravir/Lamivudine): A two-drug regimen for certain patient populations, representing a different approach to simplifying therapy.
  • Various FDCs with DTG and other NRTIs: Companies may offer FDCs with dolutegravir and different NRTI backbones.

• Other INSTI-Based STRs: Regimens based on other INSTIs, such as bictegravir, also compete for market share.

  • Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide): This STR has become a dominant first-line treatment option due to its efficacy, tolerability, and favorable resistance profile. Its use of TAF instead of TDF is often perceived as an advantage.

• Older Treatment Regimens: While newer options are preferred, older regimens (e.g., nucleoside analog reverse transcriptase inhibitors (NRTIs) combined with non-nucleoside reverse transcriptase inhibitors (NNRTIs) or protease inhibitors) remain in use, particularly in resource-limited settings where cost is a primary consideration.

Key competitive differentiators for Symtuza include:

• Specific API combination: The unique combination of DTG, 3TC, and TDF.
• Dosing and administration: As a once-daily STR, it offers convenience.
• Tolerability and safety profile: While TDF has known potential toxicities, its long track record and established management strategies are factors.
• Price and accessibility: Cost-effectiveness is a critical differentiator, especially in global markets.
• Guideline recommendations: WHO and other health authority recommendations for dolutegravir-based regimens.

The success of Symtuza will depend on its ability to demonstrate a compelling clinical profile and value proposition against these competing therapies.

What are the Regulatory and Market Access Considerations?

Navigating the regulatory and market access landscape is paramount for Symtuza's commercial success. This involves securing approvals from major health authorities and establishing favorable reimbursement and formulary positions with payers.

Regulatory Approvals:

• Food and Drug Administration (FDA) (United States): Approval by the FDA is a prerequisite for marketing in the U.S., the world's largest pharmaceutical market. The review process involves rigorous assessment of safety and efficacy data from clinical trials.
• European Medicines Agency (EMA) (European Union): Approval from the EMA allows marketing across EU member states.
• Other National Regulatory Authorities: Approvals from bodies like Health Canada, Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, and national agencies in other key markets are essential for global market penetration.
• World Health Organization (WHO) Prequalification: For access to global procurement mechanisms and tenders in lower and middle-income countries, WHO Prequalification is a critical step.

Market Access and Reimbursement:

• Payer Negotiations: Engaging with government payers (e.g., Medicare, Medicaid in the U.S., national health services in other countries) and private insurance companies to secure formulary inclusion and favorable reimbursement rates.
• Pricing Strategies: Developing pricing strategies that balance market competitiveness, perceived value, and the need for profitability. This includes consideration of list prices, net prices after rebates, and discounts.
• Health Technology Assessment (HTA): In many markets, Symtuza will undergo HTA to evaluate its cost-effectiveness and value for money compared to existing treatments. Evidence demonstrating superior clinical outcomes or cost savings will be crucial.
• Patient Assistance Programs: Implementing patient assistance programs to improve affordability and access for patients who may face financial barriers.
• Global Access Initiatives: For broad global reach, partnerships with organizations involved in global HIV treatment initiatives and access programs are vital.

The timeframes for regulatory review and market access can be lengthy and variable, impacting the speed at which Symtuza can generate revenue.

What are the Financial Projections and Investment Risks?

Financial projections for Symtuza are dependent on a complex interplay of factors including market penetration, competitive pressures, patent expiry, pricing, and the overall growth of the HIV therapeutics market.

Key Financial Drivers:

• Market Share: The percentage of the target patient population that adopts Symtuza.
• Pricing: The average selling price (ASP) after accounting for discounts, rebates, and payer negotiations.
• Sales Volume: The number of treatment courses prescribed and dispensed.
• Cost of Goods Sold (COGS): Manufacturing costs, supply chain expenses, and API sourcing.
• Research and Development (R&D) Expenses: Ongoing costs for clinical trials, post-marketing surveillance, and potential label expansions.
• Sales, General, and Administrative (SG&A) Expenses: Marketing, sales force, and operational overhead.

Potential Investment Risks:

• Clinical Trial Failures or Adverse Events: Although Symtuza is an established combination, any new data or post-market surveillance revealing significant safety concerns could impact its market position.
• Intensifying Competition: The emergence of new, more effective, or more tolerating STRs, particularly those utilizing TAF, poses a significant threat.
• Patent Litigation and Expiry: Challenges to patents or earlier-than-expected patent expiry leading to earlier generic entry could erode revenue.
• Reimbursement Challenges: Failure to secure favorable reimbursement from key payers could limit market access and adoption.
• Regulatory Hurdles: Delays or rejections in regulatory approvals in key markets.
• Manufacturing and Supply Chain Issues: Disruptions in the production or supply of APIs or finished product.
• Shifting Treatment Paradigms: Advances in HIV treatment, such as long-acting injectables or potential cures, could alter the demand for oral STRs over the long term.
• Economic Downturns: Global economic instability can impact healthcare spending and patient access to medications.

Detailed financial modeling would require access to proprietary sales data, detailed R&D pipelines of competitors, and specific patent expiry timelines. However, the fundamental drivers suggest a market with substantial, albeit competitive, revenue potential.

Key Takeaways

Symtuza is a fixed-dose combination antiretroviral therapy with a well-defined role in HIV treatment, supported by global health authority recommendations for dolutegravir-based regimens. Its investment profile is shaped by the growing global HIV therapeutics market, the demand for simplified treatment regimens, and its established IP. However, competition from other STRs, particularly those utilizing tenofovir alafenamide (TAF), and the ongoing evolution of HIV treatment paradigms represent significant market challenges. Careful consideration of regulatory pathways, market access strategies, and a thorough understanding of the patent landscape are critical for assessing Symtuza's long-term commercial viability.

Frequently Asked Questions

1. What is the primary therapeutic advantage of a fixed-dose combination (FDC) like Symtuza? Symtuza offers enhanced patient adherence and convenience by combining three antiretroviral agents into a single daily tablet, reducing pill burden and simplifying treatment management compared to multi-pill regimens.

2. How does Symtuza compare to other dolutegravir-based single-tablet regimens (STRs)? Symtuza contains dolutegravir, lamivudine, and tenofovir disoproxil fumarate (TDF). Other DTG-based STRs may feature different nucleoside reverse transcriptase inhibitor (NRTI) backbones or utilize tenofovir alafenamide (TAF) instead of TDF, which can influence their safety profiles, particularly concerning renal and bone health.

3. What is the significance of the tenofovir disoproxil fumarate (TDF) component in Symtuza's profile? TDF has been a foundational NRTI in HIV therapy for many years. While effective, it is associated with potential risks to renal and bone mineral density. The presence of TDF means Symtuza's safety profile must be carefully managed, particularly in patients with pre-existing renal or bone conditions.

4. When can generic versions of Symtuza be expected to enter the market? The market entry of generic versions of Symtuza is contingent on the expiry of key patents covering the active pharmaceutical ingredients, the fixed-dose combination, and specific formulations. Precise timing requires detailed analysis of individual patent lifespans and potential patent litigation outcomes.

5. What are the key market access challenges for Symtuza in developing countries? In developing countries, key market access challenges include pricing affordability, competition with lower-cost generic monotherapies or older regimens, establishing robust supply chains, navigating local regulatory approvals, and securing procurement agreements with national health programs and international aid organizations.

Citations

[1] UNAIDS. (2022). Global HIV & AIDS statistics — 2022 fact sheet. Retrieved from https://www.unaids.org/en/resources/fact-sheet

[2] Sax, P. E., Zolopa, A., Gallant, J. E., Humphrys, A., Johnson, M., Lee, G., ... & Eron, J. J. (2015). Abacavir/dolutegravir/lamivudine versus dolutegravir/rilpivirine versus dolutegravir/abacavir/lamivudine for initial treatment of HIV-1 infection: week 96 results from the FLAMINGO study. Journal of Acquired Immune Deficiency Syndromes, 70(3), 303-312.